ACOG issues new advice on preventing thromboembolism during C/S

Article

New recommendations from the American College of Obstetricians and Gynecologists (ACOG) urge placing inflatable compression devices on the legs of women undergoing cesarean delivery to prevent thromboembolism and reduce maternal mortality. Practice Bulletin #123, published in Obstetrics and Gynecology (2011; 118[3]:718-729), updates guidelines on preventing, managing, and treating thromboembolism during pregnancy.

New recommendations from the American College of Obstetricians and Gynecologists (ACOG) urge placing inflatable compression devices on the legs of women undergoing cesarean delivery to prevent thromboembolism and reduce maternal mortality. Practice Bulletin #123, published in Obstetrics and Gynecology (2011; 118[3]:718-729), updates guidelines on preventing, managing, and treating thromboembolism during pregnancy.

Pregnancy is associated with a fourfold increase in the risk of venous thromboembolism (VTE) because of physiological changes such as easier clotting, slower blood flow, compression of veins in the pelvis, and reduced mobility. Other risk factors include a personal history of VTE, thrombophilia, obesity, hypertension, and smoking. 

“Cesarean delivery is an independent risk factor for thromboembolic events-it nearly doubles a woman’s risk,” said Andra H. James, MD, who helped develop the guidelines. “Fitting inflatable compression devices on a woman’s legs before cesarean delivery is a safe, potentially cost-effective preventive intervention.” However, ACOG warns against delaying an emergency cesarean delivery to apply compression devices. Compression sleeves should be left in place until a woman can walk after delivery or until anticoagulation medication is resumed in women who had been receiving it during pregnancy.

The guidelines also call for prophylaxis with anticoagulants for women who have suffered an acute VTE during pregnancy, have a history of thrombosis, or are at significant risk for VTE during pregnancy and postpartum, including women with high-risk acquired or inherited thrombophilia. Pregnant women with a history of thrombosis should be evaluated for underlying causes to determine whether anticoagulation is appropriate. Most women who take anticoagulants before pregnancy will need to do so during pregnancy and after delivery.

“Because half of VTE-related maternal deaths occur during pregnancy and the rest during the postpartum period, ongoing patient assessment is imperative,” James says. “While warning signs in some women may be evident early in pregnancy, others will develop symptoms that manifest later in pregnancy or after the baby is born.”

Read other articles in this issue of Special Delivery.

Recent Videos
Supreme Court upholds mifepristone access: Implications for women's health | Image Credit: linkedin.com
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
© 2024 MJH Life Sciences

All rights reserved.